department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Vizz · pharmadog

pharmadog
drugs
Vizz

drug

patient view →

aceclidine

Marketedupdated 2mo ago

by $LENZ LENZ Therapeutics, Inc.

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Vizz

generic

aceclidine

indication

Presbyopia

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 25m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 31, 2030

~4.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

Mar 15, 2044method-of-use (U-3741)US 12414942
Oct 8, 2039method-of-use (U-3741)US 12128036
Oct 8, 2039method-of-use (U-3741)US 12533347
Mar 24, 2034formulationUS 10052313
Mar 24, 2034method-of-use (U-3741)US 11179328
Mar 24, 2034formulationUS 9844537

FDA exclusivities (1)

Jul 31, 2030NCENew Chemical Entity (5y)4.1y

Trials studying aceclidine

phase3Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopiacompletedn=300
phase3Phase 3 Safety Study for the Treatment of Presbyopia Subjectscompletedn=362
phase1Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopiacompletedn=21
phase1Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopiacompletedn=30